- Home
- » Tags
- » Proteasome inhibitor
Top View
- COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
- KYPROLIS (Carfilzomib) for Injection Is an Antineoplastic Agent Available for Intravenous Use Only
- Terazosin Suppress Human Prostatic Cancer PC3 Cell Viability Via Proteasome
- Lessons from Multiple Myeloma and Mantle Cell Lymphoma Maria Gonzalez-Santamarta, Grégoire Quinet, Diana Reyes-Garau, Brigitte Sola, Gaël Roué, Manuel Rodriguez
- Targeting Steroid Hormone Receptors for Ubiquitination and Degradation in Breast and Prostate Cancer
- The Combination of Cyclophosphamide, Velcade and Dexamethasone Respec- 19% in the CVD Group, 15% in the VD Group and 45% Tively
- Mechanism of Action of Bortezomib in Multiple Myeloma Therapy
- Velcade, INN-Bortezomib
- NINLARO® (Ixazomib) Oral Capsule
- Proteasome Inhibitors As Experimental Therapeutics of Autoimmune Diseases Sue Ellen Verbrugge1, Rik J Scheper2, Willem F Lems1, Tanja D De Gruijl3 and Gerrit Jansen1*
- Proteasome Function Is Required for DNA Damage Response and Fanconi Anemia Pathway Activation
- Discovery of Drug Mode of Action and Drug Repositioning from Transcriptional Responses
- Sarclisa, INN-Isatuximab
- A Practical Review of Proteasome Pharmacology
- Disabling the Protease DDI2 Attenuates the Transcriptional Activity of NRF1 and Potentiates Proteasome Inhibitor Cytotoxicity
- Repair of DNA-Protein Crosslinks in Plants T Leonie Hacker, Annika Dorn, Holger Puchta*
- Targeting Steroid Hormone Receptors for Ubiquitination and Degradation in Breast and Prostate Cancer
- The Development of Proteasome Inhibitors As Anticancer Drugs
- Inhibition of Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 2
- Borcade190x280 R
- Proteasome Inhibitors Bortezomib and Carfilzomib Stimulate the Transport Activity Of
- Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management
- Statistical Analysis Plan Version 2.0
- The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice
- Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib Against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
- The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Can Sensitize Human Lymphoma to Cyclophosphamide
- The Proteasome As a Target for Cancer Therapy
- HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do Not Include All the Information Needed to Use NINLARO Safely and Effec
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
- Genetic and Pharmacologic Evidence That Mtor Targeting Outweighs Mtorc1 Inhibition As an Antimyeloma Strategy
- Next-Generation Proteasome Blockers Promise Safer Cancer Therapy
- The Proteasome Inhibitor Bortezomib Inhibits the Release of Nfκb-Inducible Cytokines and Induces Apoptosis of Activated T Cells from Rheumatoid Arthritis Patients J.W
- The Role of the Ubiquitin Proteasome System in Lymphoma
- Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity
- From Proteasome Inhibitors to Immunotherapy James J
- Intrinsic and Extrinsic Factors Affecting Proteasome Inhibitor Resistance in Multiple Myeloma
- Lactacystin: first-In-Class Proteasome Inhibitor Still Excelling and an Exemplar for Future Antibiotic Research
- Topoisomerase I Inhibitors: Camptothecins and Beyond
- Bortezomib Improved the Joint Manifestations of Rheumatoid Arthritis in Three Patients
- Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers
- Ixazomib: the First Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
- Proteasome Inhibitor MG132 Is Toxic and Inhibits the Proliferation of Rat Neural Stem Cells but Increases BDNF Expression to Protect Neurons
- Mtor Inhibition Activates Overall Protein Degradation by the Ubiquitin Proteasome System As Well As by Autophagy